Clinical trials
Lung Neoplasm Malignant clinical trials
Below are recruiting lung neoplasm malignant clinical trials, each written for real people, not researchers. We’re tracking 170 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04858009RecruitingPhase 2
Warm chemotherapy placed in the belly for pancreatic cancer spread
This Phase 2 study tests a treatment that warms chemotherapy and delivers it directly into the abdomen to treat pancreatic cancer that has spread to the lining of the belly (peritoneum). You may be eligible if you completed earlier chemotherapy and your body shows signs the cancer is responding, with limited spread in the abdomen.
Rochester, MinnesotaAges 18–80 - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT05248763Recruiting
Cancer Moonshot program for specific cancer types
This study is for people with certain cancers: lung, breast, gastric (stomach), pancreatic, or ovarian. It aims to test a Moonshot-style approach to improve cancer care for these groups.
TaipeiAges 20 years+ - NCT05693363Recruiting
Scan lung tissue with a PET-CT during thoracic surgery
This study tests whether a special imaging scan using a radioactive sugar (18F-FDG) can help doctors better examine lung cancer tissue during thoracic surgery. You may be offered the scan around the time of your operation to help researchers learn how well it works.
GhentAges 18 years+ - NCT05918445RecruitingPhase 1/Phase 2
PM8002 for advanced solid tumors that have stopped responding
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
BaojiAges 18–75 - NCT06200831Recruiting
Same surgery or two surgeries for colorectal cancer with liver spread
This trial compares having one surgery to remove both the colon tumor and liver tumors at the same time versus having two separate surgeries. It aims to find which approach is safer and works better for patients whose cancer has spread only to the liver.
OsloAges 18–80 - NCT06208371RecruitingPhase 3
Local treatment vs. chemo for colorectal cancer with many liver spots
This trial tests whether treating all liver tumors with surgery, ablation, or radiation is better than continuing standard chemotherapy for people with colorectal cancer that has spread only to the liver. It's for those whose liver tumors have been controlled by initial chemotherapy and are considered removable.
Guangzhou, GuangdongAges 18 years+ - NCT06240728RecruitingPhase 1
Testing NPX887 for advanced solid tumors with B7-H7 protein
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
Baltimore, MarylandAges 18 years+ - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06643793RecruitingPhase 2
Irinotecan liposome combo for advanced colorectal cancer
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT07291921Recruiting
Blood tests before and after lung cancer surgery
This study looks at changes in small molecules, genetic material, and other markers in the blood before and after lung cancer surgery. The goal is to develop a simple blood test to monitor patients over time and see if the cancer comes back.
Beijing, Beijing MunicipalityAges 18–85 - NCT05376878RecruitingPhase 4
PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT04893785RecruitingPhase 2
Cabozantinib plus temozolomide for advanced neuroendocrine lung tumors
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
Naples, CampaniaAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Dublin, CaliforniaAges 18 years+ - NCT06587490RecruitingPhase 3
Radiation therapy for limited metastatic cancers
This trial tests whether adding focused, high-dose radiation (SABR) to standard drug therapy can better control cancer that has spread to a few spots in the body. It is for people starting or resuming cancer medicines for newly found or growing metastases.
La Jolla, CaliforniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT07162038RecruitingPhase 1
Combining CAR-T cells with a stem cell transplant for blood cancers
This trial tests adding anti-CD19 CAR-T cells to a half-matched stem cell transplant for people with high-risk blood cancers. The goal is to see if this combination is safe and can improve outcomes.
Bethesda, MarylandAges 18–75 - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Mobile, AlabamaAges 18 years+ - NCT00071045Enrolling by invitation
Tissue Collection From Cancer and Blood Disorder Patients
This study collects tissue samples from patients with cancer or blood disorders, and from their matching family members who might donate stem cells for transplant. The samples help researchers understand these diseases and develop better treatments.
Bethesda, MarylandAges 2–100 - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+
Hear when a new Lung Neoplasm Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung neoplasm malignant?
- Yes. Clin2 currently lists 170 recruiting lung neoplasm malignant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung neoplasm malignant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung neoplasm malignant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.